Cargando…

Distribution of Paraoxonase-1 (PON-1) and Lipoprotein Phospholipase A2 (Lp-PLA2) across Lipoprotein Subclasses in Subjects with Type 2 Diabetes

Paraoxonase-1 (PON1) and lipoprotein phospholipase A2 (Lp-PLA2) may exert an important protective role by preventing the oxidative transformation of high- and low-density lipoproteins (HDL and LDL, respectively). The activity of both enzymes is influenced by lipidome and proteome of the lipoprotein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passaro, Angelina, Vigna, Giovanni Battista, Romani, Arianna, Sanz, Juana M., Cavicchio, Carlotta, Bonaccorsi, Gloria, Valacchi, Giuseppe, Cervellati, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247389/ https://www.ncbi.nlm.nih.gov/pubmed/30524650 http://dx.doi.org/10.1155/2018/1752940

Ejemplares similares

Sex Difference Impacts on the Relationship between Paraoxonase-1 (PON1) and Type 2 Diabetes
por: Rosta, Valentina, et al.
Publicado: (2020)

Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A(2 )(Lp-PLA(2 )): a review
por: Silva, Isis T, et al.
Publicado: (2011)

Lipoprotein-Associated Phospholipase A2 (Lp-PLA(2)): A Novel and Promising Biomarker for Cardiovascular Risks Assessment
por: Cai, Anping, et al.
Publicado: (2013)

Lipoprotein-associated phospholipase A2 (Lp-PLA2) – possible diagnostic and risk biomarker in chronic ischaemic heart disease
por: Diaconu, Adriana, et al.
Publicado: (2020)

Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1
por: Trentini, Alessandro, et al.
Publicado: (2019)

STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A(2) (Lp-PLA(2)) as a biomarker or risk factor for cardiovascular diseases
por: Hassan, Mohamed
Publicado: (2015)

Relationship of lipoprotein-associated phospholipase A2(Lp-PLA2) and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention
por: Yin, Yun-jie, et al.
Publicado: (2020)

Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity in adolescents: the healthy young cross-sectional study
por: da Silva, Isis T, et al.
Publicado: (2013)

Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A(2) (Lp-PLA(2)) Inhibitor [(18)F]GSK2647544 in Healthy Male Subjects
por: Huiban, Mickael, et al.
Publicado: (2016)

Lipoprotein-associated phospholipase A(2 )(Lp-PLA(2)) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults
por: Detopoulou, Paraskevi, et al.
Publicado: (2009)

Resveratrol Treatment Is Associated with Lipid Regulation and Inhibition of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Rabbits Fed a High-Fat Diet
por: Xu, Lei, et al.
Publicado: (2020)

The Utility of the Lipoprotein-Associated Phospholipase A(2) (Lp-PLA(2)) Assay in Detecting Abnormalities in Lipid Metabolism and Cardiovascular Risk in an HIV-Infected South African Cohort
por: Mayne, Elizabeth S., et al.
Publicado: (2019)

Lipoprotein-Associated Phospholipase A2 Activity as Potential Biomarker of Vascular Dementia
por: Zuliani, Giovanni, et al.
Publicado: (2023)

Crosstalk Between Adipokines and Paraoxonase 1: A New Potential Axis Linking Oxidative Stress and Inflammation
por: Tisato, Veronica, et al.
Publicado: (2019)

Lactonase Activity and Lipoprotein-Phospholipase A(2) as Possible Novel Serum Biomarkers for the Differential Diagnosis of Autism Spectrum Disorders and Rett Syndrome: Results from a Pilot Study
por: Hayek, Joussef, et al.
Publicado: (2017)

Oxidized phospholipids and lipoprotein-associated phospholipase A(2) as important determinants of Lp(a) functionality and pathophysiological role
por: Tselepis, Alexandros D.
Publicado: (2018)

Association of Carotid Plaque and Serum Lipoprotein-Associated Phospholipase A2 (LP-PLA2) with Postoperative Delirium in Geriatric Patients Undergoing Hip Replacement: A Prospective Cohort Study
por: Wan, Tiantian, et al.
Publicado: (2020)

Human Paraoxonase-2 (PON2): Protein Functions and Modulation
por: Manco, Giuseppe, et al.
Publicado: (2021)

Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis
por: Zuin, Marco, et al.
Publicado: (2022)

Effect of propolis and N-acetylcysteine supplementation on lipoprotein subclasses distribution and paraoxonase 1 activity in subjects with acute respiratory infection
por: Vekić, Jelena, et al.
Publicado: (2020)

A Review of Novel Cardiac Biomarkers in Acute or Chronic Cardiovascular Diseases: The Role of Soluble ST2 (sST2), Lipoprotein-Associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO), and Procalcitonin (PCT)
por: Li, Junpei, et al.
Publicado: (2021)

Paraoxonases (PON) 1, 2, and 3 Polymorphisms and PON-1 Activities in Patients with Sickle Cell Disease
por: Reichert, Cadiele Oliana, et al.
Publicado: (2019)

Lipoprotein‐associated phospholipase A2: The story continues
por: Huang, Fubao, et al.
Publicado: (2019)

Lp-PLA2 Inhibition—The Atherosclerosis Panacea?
por: Karakas, Mahir, et al.
Publicado: (2010)

Paraoxonase 2 (PON2) plays a limited role in murine lung tumorigenesis
por: Whitt, Aaron G., et al.
Publicado: (2023)

Interactome of Paraoxonase PON2 Reveals New Pathways for Tumor Growth Regulation
por: Karlov, V. D., et al.
Publicado: (2023)

Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease
por: Doody, Rachelle S., et al.
Publicado: (2015)

The Association between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Low-density Lipoprotein Subclasses
por: Moriyama, Kengo
Publicado: (2020)

Lp-PLA(2) Inhibitors for the Reduction of Cardiovascular Events
por: Steen, Dylan L., et al.
Publicado: (2013)

Lp-PLA2 levels in HIV-infected patients
por: Díaz-Pollán, Beatriz, et al.
Publicado: (2014)

Serum paraoxonase 1 (PON1) measurement: an update
por: Ceron, Jose J, et al.
Publicado: (2014)

Genetic invalidation of Lp-PLA(2) as a therapeutic target: Large-scale study of five functional Lp-PLA(2)-lowering alleles
por: Gregson, John M, et al.
Publicado: (2016)

Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis
por: Riedmaier, Stephan, et al.
Publicado: (2011)

Evaluation of Paraoxonase, Malondialdehyde, and Lipoprotein Levels in Patients with Asymptomatic Cholelithiasis
por: Atamer, Aytac, et al.
Publicado: (2014)

PON1 concentration and high-density lipoprotein characteristics as cardiovascular biomarkers
por: González, Fátima E. Murillo, et al.
Publicado: (2019)

Racial variation in lipoprotein-associated phospholipase A(2 )in older adults
por: Lee, Keane K, et al.
Publicado: (2011)

Secreted phospholipase A(2), lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics
por: Yamamoto, Kei, et al.
Publicado: (2011)

Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis
por: Wang, Yuan, et al.
Publicado: (2022)

A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass
por: Qi, Yue, et al.
Publicado: (2016)

Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China
por: Huang, Yuli, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_abe9dnb53hsjk7asnkv13fc0dj